Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nephrotic Syndromes Clear all
Completed Phase 2 Interventional Results available

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

NCT01601236
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 2Phase 3 Interventional

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

NCT00035334
View directory record Official record
Conditions
Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome, Kidney Diseases, Gastrointestinal Diseases
Interventions
NC-503 (Anti-amyloidotic (AA) Agent)
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2006 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 4 Interventional

Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes

NCT01021540
View directory record Official record
Conditions
Nephrotic Syndromes
Interventions
Repository corticotrophin
Drug
Lead sponsor
Arizona Kidney Disease and Hypertension Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Sep 12, 2026, 8:23 AM EDT
Terminated Phase 3 Interventional Results available

Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome

NCT02390362
View directory record Official record
Conditions
Frequent Relapsing Nephrotic Syndrome, Steroid Dependent Nephrotic Syndrome
Interventions
Rituximab, MMF
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 3 Interventional

Prednisolone Trial in Children Younger Than 4 Years

NCT03141970
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
Prednisolone
Drug
Lead sponsor
All India Institute of Medical Sciences
Other
Eligibility
1 Year to 4 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Stanford, California • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 12, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional

Diuretic Tuner Clinical Decision Support

NCT04759274
View directory record Official record
Conditions
Edema, Hypervolemia, Chronic Kidney Diseases, Nephrotic Syndrome
Interventions
Diuretic Tuner
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 12, 2026, 8:23 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure

NCT02194582
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure, Unexplained Proteinuria
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
2,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional Results available

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

NCT03703908
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
CCX140-B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Torrance, California • Shreveport, Louisiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

NCT04009668
View directory record Official record
Conditions
FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
adalimumab
Drug
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Ann Arbor, Michigan • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 12, 2026, 8:23 AM EDT
Recruiting Phase 2 Interventional

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135
View directory record Official record
Conditions
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions
WAL0921, Placebo
Drug
Lead sponsor
Walden Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis

NCT00004990
View directory record Official record
Conditions
Glomerulonephritis, Nephrotic Syndrome
Interventions
Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 12, 2026, 8:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glucocorticoid-induced Osteopenia in Children

NCT00289328
View directory record Official record
Conditions
Crohn's Disease, Nephrotic Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years to 21 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

NCT02000440
View directory record Official record
Conditions
Glomerulosclerosis, Focal Segmental
Interventions
Losmapimod
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Stanford, California • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Apixaban in Nephrotic Syndrome

NCT02599532
View directory record Official record
Conditions
Nephrotic Syndrome, Proteinuria
Interventions
apixaban
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 79 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 12, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional

Steroid Sensitive Nephrotic Syndrome in Children

NCT03878914
View directory record Official record
Conditions
Nephrotic Syndrome in Children
Interventions
Corticosteroids
Drug
Lead sponsor
Wayne State University
Other
Eligibility
1 Year to 18 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 12, 2026, 8:23 AM EDT
Not listed No phase listed Observational

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

NCT03644771
View directory record Official record
Conditions
Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function
Interventions
Acthar
Drug
Lead sponsor
Greater Boston Medical Associates
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome

NCT04278729
View directory record Official record
Conditions
Nephrotic Syndrome, Membranous Nephropathy
Interventions
Apixaban 5 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 79 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

NCT01613118
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
RE-021 (Sparsentan), Irbesartan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
8 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
28
States / cities
San Diego, California • Torrance, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 12, 2026, 8:23 AM EDT
Recruiting No phase listed Observational

Immune System Related Kidney Disease

NCT00001979
View directory record Official record
Conditions
Kidney Disease, Nephrotic Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
10 Years to 99 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Podocyte Retinoids

NCT00098020
View directory record Official record
Conditions
Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental
Interventions
Isotretinoin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 12, 2026, 8:23 AM EDT
Terminated Phase 2 Interventional

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

NCT04950114
View directory record Official record
Conditions
Kidney Diseases, Glomerulosclerosis, Focal Segmental Nephrosis, Lipoid Urologic Disease, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Los Angeles, California • Northridge, California • Victorville, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 12, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional

NEPTUNE Match Study

NCT04571658
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions
Communication
Other
Lead sponsor
University of Michigan
Other
Eligibility
1 Year to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 12, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 12, 2026, 8:23 AM EDT
Terminated No phase listed Observational

A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

NCT04235621
View directory record Official record
Conditions
Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
Interventions
FSGS/TR-MCD, Diabetic Nephropathy (DN)
Other
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Mesa, Arizona • Glendale, California • Victorville, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 12, 2026, 8:23 AM EDT